HIV Care and Services Outside the US

"We have never been silent, but you have not heard us": Advocates demonstrate to demand inclusion of indigenous issues in the HIV response.

The ECHO trial faces backlash and criticism.

Activists working on human rights discuss the challenges of achieving an end to the HIV epidemic.

ECHO trial results and follow-up studies find unexpectedly low rates of some STIs among users of certain long-term hormonal contraceptives. They also find high HIV rates (unrelated to the contraceptives) that suggest considerable value for PrEP integration.

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.

"We don't need to spend another $140 million to find out how to retain people in care," activist David Barr writes. "We need to invest in the kinds of services people need so that they can use treatment easily and effectively."

Atripla may be just as effective when taken every other day; poor antiretroviral prescription fill rates after hospitalization; U.S. progress against UNAIDS targets; hepatitis C transmission clustering in France.

"Placing more attention on meeting the sexual health and holistic wellness needs of gay men affected by sexualized substance use is critical," writes the associate director of Ontario's Gay Men's Sexual Health Alliance.

Although the move means that more Britons might be able to access free PrEP, this study is also controversial for being seen as a way to delay full government approval.